

Urinary Excretion of Leukotriene E₄ and 11-dehydro-Th₁₃ Bronchial Provocations with Allergen, Aspirin, Leukotri Asthmatics

The American Review of Respiratory Disease

146, 96-103

DOI: 10.1164/ajrccm/146.1.96

Citation Report

#	ARTICLE	IF	CITATIONS
1	Agonist-induced lipoxin A4 generation: Detection by a novel lipoxin A4-ELISA. <i>Lipids</i> , 1993, 28, 1047-1053.	1.7	54
2	Efficacy and Tolerability of Nimesulide in Asthmatic Patients Intolerant to Aspirin. <i>Drugs</i> , 1993, 46, 115-120.	10.9	63
3	The Pivotal Role of 5-Lipoxygenase Products in the Reaction of Aspirin-sensitive Asthmatics to Aspirin. <i>The American Review of Respiratory Disease</i> , 1993, 148, 1447-1451.	2.9	368
4	Mechanism of Bronchospasm in Aspirin-sensitive Asthma. <i>The American Review of Respiratory Disease</i> , 1993, 148, 1442-1443.	2.9	26
5	Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects.. <i>Thorax</i> , 1993, 48, 1205-1210.	5.6	107
6	Sulphidopeptide Leukotrienes in Asthma. <i>Clinical Science</i> , 1993, 84, 501-510.	4.3	68
7	Leukotrienes and aspirin induced asthma.. <i>Thorax</i> , 1993, 48, 1189-1190.	5.6	11
8	Inhibition of analgesic-induced asthma by leukotriene receptor antagonist ONO-1078.. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1994, 150, 254-257.	5.6	111
9	Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma.. <i>Thorax</i> , 1994, 49, 749-756.	5.6	95
10	Effect of the 5-lipoxygenase inhibitor ZD2138 on allergen-induced early and late asthmatic responses.. <i>Thorax</i> , 1994, 49, 743-748.	5.6	52
11	Antipyretic analgesics. <i>Side Effects of Drugs Annual</i> , 1994, 18, 90-98.	0.6	0
12	Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge.. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1994, 149, 940-946.	5.6	152
13	Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma. <i>Journal of Allergy and Clinical Immunology</i> , 1994, 94, 1046-1056.	2.9	161
14	Leukotriene Receptor Antagonists and Biosynthesis Inhibitors in Asthma. <i>BioDrugs</i> , 1994, 2, 220-232.	0.7	8
15	Leukotrienes as a Target in Asthma Therapy. <i>Drugs</i> , 1994, 47, 12-24.	10.9	60
16	The leukotriene-antagonist ICI-204,219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmatics. <i>European Respiratory Journal</i> , 1994, 7, 324-331.	6.7	85
17	Time-limited protective effect of inhaled frusemide against aspirin-induced bronchoconstriction in aspirin-sensitive asthmatics. <i>European Respiratory Journal</i> , 1994, 7, 1825-1829.	6.7	8
18	Leukotriene receptor antagonists and biosynthesis inhibitors: potential breakthrough in asthma therapy. <i>European Respiratory Journal</i> , 1995, 8, 1203-1213.	6.7	79

#	ARTICLE	IF	CITATIONS
19	Allergen-induced late-phase airways obstruction in the pig: mediator release and eosinophil recruitment. <i>European Respiratory Journal</i> , 1995, 8, 1100-1109.	6.7	31
20	Aspirin Sensitive Rhinosinusitis and Asthma. <i>Allergy and Asthma Proceedings</i> , 1995, 16, 77-80.	2.2	10
21	Elevated Urinary Leukotriene E ₄ in Chronic Lung Disease of Extreme Prematurity. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1995, 151, 841-845.	5.6	21
22	Leukotrienes as mediators of airway obstruction and inflammation in asthma. <i>Clinical and Experimental Allergy</i> , 1995, 25, 50-54.	2.9	27
23	Validation and application of a new simple strategy for measurements of urinary leukotriene E ₄ in humans. <i>Clinical and Experimental Allergy</i> , 1995, 25, 467-479.	2.9	109
24	Clinical studies with agents active on the 5-lipoxygenase pathway. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 1995, 50, 22-26.	5.7	10
25	Leukotrienes as therapeutic target in asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 1995, 50, 615-622.	5.7	32
26	Chemical Regulation of Pulmonary Airway Tone. <i>Annual Review of Physiology</i> , 1995, 57, 151-170.	13.1	15
27	D-penicillamine inhibits the action of reactive oxygen species in the pig pulmonary circulation. <i>Journal of Perinatal Medicine</i> , 1995, 23, 385-394.	1.4	12
28	The effect of aspirin desensitization on urinary leukotriene E ₄ concentrations in aspirin-sensitive asthma.. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1995, 151, 1326-1330.	5.6	81
29	Cellular infiltration and eicosanoid synthesis in brown Norway rat lungs after allergen challenge.. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1995, 13, 477-486.	2.9	22
30	Cysteinyl leukotrienes in asthma: current state of therapeutic evaluation.. <i>Thorax</i> , 1995, 50, 1005-1010.	5.6	10
31	Eicosanoids and asthma: an update. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 1995, 52, 271-288.	2.2	59
32	Impairment of renal function after treatment of a burn patient with diclofenac, a non-steroidal anti-inflammatory drug. <i>Burns</i> , 1995, 21, 471-473.	1.9	16
33	Arachidonic acid metabolism in the human mast cell line HMC-1: 5-lipoxygenase gene expression and biosynthesis of thromboxane. <i>Lipids and Lipid Metabolism</i> , 1995, 1257, 58-74.	2.6	32
34	Inhibition of monocyte leukotriene B production after aspirin desensitization. <i>Journal of Allergy and Clinical Immunology</i> , 1995, 96, 148-156.	2.9	71
35	Diurnal variation of urinary leukotriene E ₄ and histamine excretion rates in normal subjects and patients with mild-to-moderate asthma. <i>Journal of Allergy and Clinical Immunology</i> , 1995, 96, 643-651.	2.9	88
36	Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: Long-term outcomes. <i>Journal of Allergy and Clinical Immunology</i> , 1996, 98, 751-758.	2.9	273

#	ARTICLE	IF	CITATIONS
37	Increased urinary excretion of the prostaglandin D2 metabolite 9 β ,11 β -prostaglandin F2 after aspirin challenge supports mast cell activation in aspirin-induced airway obstruction. Journal of Allergy and Clinical Immunology, 1996, 98, 421-432.	2.9	163
38	Urinary leukotriene E4 in the assessment of nocturnal asthma. Journal of Allergy and Clinical Immunology, 1996, 97, 735-741.	2.9	53
39	Selenite Incubated with NADPH and Mammalian Thioredoxin Reductase Yields Selenide, Which Inhibits Lipoxygenase and Changes the Electron Spin Resonance Spectrum of the Active Site Iron. Biochemistry, 1996, 35, 8511-8516.	2.5	50
40	Analytical methods for the measurement of leukotrienes and other eicosanoids in biological samples from asthmatic subjects. Journal of Chromatography A, 1996, 725, 29-40.	3.7	22
41	Biology and pathophysiology of leukotrienes. Critical Reviews in Oncology/Hematology, 1996, 23, 167-223.	4.4	34
42	Simplified method for measuring urinary leukotriene E4. Biomedical Applications, 1996, 677, 152-155.	1.7	9
43	Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma.. American Journal of Respiratory and Critical Care Medicine, 1996, 153, 572-575.	5.6	252
44	Anti-Leukotriene Agents: A New Direction in Asthma Therapy. Journal of Asthma, 1996, 33, 353-366.	1.7	13
45	Leukotrienes in Asthma. Archives of Internal Medicine, 1996, 156, 2181.	3.8	38
46	Bronchial aspirin challenge causes specific eicosanoid response in aspirin-sensitive asthmatics.. American Journal of Respiratory and Critical Care Medicine, 1996, 154, 1608-1614.	5.6	175
47	Expression of Interleukin-5 and Granulocyte-Macrophage Colony-stimulating Factor in Aspirin-sensitive and Non-Aspirin-sensitive Asthmatic Airways. American Journal of Respiratory and Critical Care Medicine, 1997, 156, 1384-1389.	5.6	62
48	Inhibition of allergen-induced airway obstruction and leukotriene generation in atopic asthmatic subjects by the leukotriene biosynthesis inhibitor BAYx 1005. Thorax, 1997, 52, 342-347.	5.6	52
49	Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. Thorax, 1997, 52, 1030-1035.	5.6	191
50	Profound Overexpression of Leukotriene C ₄ Synthase in Bronchial Biopsies from Aspirin-Intolerant Asthmatic Patients. International Archives of Allergy and Immunology, 1997, 113, 355-357.	2.1	95
52	Effects of single-dose zileuton on bronchial hyperresponsiveness in asthmatic patients treated with inhaled corticosteroids. European Respiratory Journal, 1997, 10, 2749-2753.	6.7	17
53	Leukotriene Activity Modulation in Asthma. Drugs, 1997, 54, 369-384.	10.9	24
54	Theophylline infusion modulates prostaglandin and leukotriene production in man. Prostaglandins Leukotrienes and Essential Fatty Acids, 1997, 57, 555-560.	2.2	6
55	Childhood asthma and allergic rhinitis: the role of leukotrienes. Journal of Pediatrics, 1997, 131, 348-355.	1.8	31

#	ARTICLE	IF	CITATIONS
56	Leukotrienes in the Pathogenesis of Asthma. Chest, 1997, 111, 27S-34S.	0.8	121
57	Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. Clinical Therapeutics, 1997, 19, 675-690.	2.5	149
58	Measurements of leukotrienes in the urine: strategies and applications. Allergy: European Journal of Allergy and Clinical Immunology, 1997, 52, 124-135.	5.7	43
59	Urinary leukotriene E4 and 11-dehydrothromboxane B2 in patients with aspirin-sensitive asthma. Allergy: European Journal of Allergy and Clinical Immunology, 1997, 52, 470-473.	5.7	38
60	Mechanism of aspirin-induced asthma. Allergy: European Journal of Allergy and Clinical Immunology, 1997, 52, 613-619.	5.7	98
61	Aspirin-induced asthma and HLA-DRB1 and HLA-DPB1 genotypes. Clinical and Experimental Allergy, 1997, 27, 574-577.	2.9	97
62	A novel thromboxane synthetase inhibitor, DP-1904, inhibits human blood eosinophil degranulation. Inflammation, 1997, 21, 1-8.	3.8	4
63	The effects of a novel sulphidopeptide leukotriene antagonist, BAY x7195, against elicited bronchoconstriction in the anaesthetized guinea pig. British Journal of Pharmacology, 1998, 123, 39-44.	5.4	4
64	Immunoaffinity Resin for Purification of Urinary Leukotriene E4. Prostaglandins and Other Lipid Mediators, 1998, 55, 301-321.	1.9	26
65	Can asthma be studied in the urine?. Clinical and Experimental Allergy, 1998, 28, 129-133.	2.9	19
66	Urinary excretion of inflammatory mediators during allergen-induced early and late phase asthmatic reactions. Clinical and Experimental Allergy, 1998, 28, 1332-1339.	2.9	91
67	Lipid mediator pathways in the lung: leukotrienes as a new target for the treatment of asthma. Clinical and Experimental Allergy, 1998, 28, 141-146.	2.9	15
69	Leukotriene antagonism in asthma and rhinitis. Respiratory Medicine, 1998, 92, 795-809.	2.9	17
70	A Single Dose of Zafirlukast Reduces LTD4-Induced Bronchoconstriction in Patients on Maintenance Inhaled Corticosteroid Therapy. Annals of Allergy, Asthma and Immunology, 1998, 81, 43-49.	1.0	29
71	The Role and Contribution of Leukotrienes in Asthma. Annals of Allergy, Asthma and Immunology, 1998, 81, 17-29.	1.0	33
72	Respiratory Syncytial Virus Induces the Expression of 5-Lipoxygenase and Endothelin-1 in Bronchial Epithelial Cells. Biochemical and Biophysical Research Communications, 1998, 251, 704-709.	2.1	73
73	Zafirlukast. Drugs, 1998, 55, 121-144.	10.9	70
74	Exposure of healthy volunteers to swine house dust increases formation of leukotrienes, prostaglandin D2, and bronchial responsiveness to methacholine. Thorax, 1998, 53, 1041-1046.	5.6	31

#	ARTICLE	IF	CITATIONS
75	Benefits from Adding the 5-Lipoxygenase Inhibitor Zileuton to Conventional Therapy in Aspirin-intolerant Asthmatics. American Journal of Respiratory and Critical Care Medicine, 1998, 157, 1187-1194.	5.6	372
76	Leukotrienes as Mediators of Airway Obstruction. American Journal of Respiratory and Critical Care Medicine, 1998, 158, S193-S200.	5.6	89
77	Effects of Cysteinyl-Leukotriene Receptor Antagonist, Thromboxane A2 Receptor Antagonist, and Thromboxane A2 Synthetase Inhibitor on Antigen-Induced Bronchoconstriction in Patients With Asthma. Chest, 1998, 114, 1028-1032.	0.8	19
78	Difficult asthma. European Respiratory Journal, 1998, 12, 1209-1218.	6.7	225
79	The Many Faces of Airway Inflammation. American Journal of Respiratory and Critical Care Medicine, 1999, 159, S1-S63.	5.6	104
80	Arachidonic Acid Metabolism in Nasal Tissue and Peripheral Blood Cells in Aspirin Intolerant Asthmatics. Acta Oto-Laryngologica, 1999, 119, 277-280.	0.9	55
81	Treatment of Asthma with Drugs Modifying the Leukotriene Pathway. New England Journal of Medicine, 1999, 340, 197-206.	27.0	778
82	Early increase in urinary leukotriene E4 (LTE4) is dependent on allergen dose inhaled during bronchial challenge in asthmatic subjects. Allergy: European Journal of Allergy and Clinical Immunology, 1999, 54, 1278-1285.	5.7	13
83	Biosynthesis of cysteinyl-leucotrienes in aspirin-intolerant asthma. Clinical and Experimental Allergy, 1999, 29, 306-313.	2.9	37
84	Experimental models in asthma. Clinical and Experimental Allergy, 1999, 29, 82-86.	2.9	8
85	Asthma and leukotrienes: antileukotrienes as novel antiasthmatic drugs. Journal of Internal Medicine, 1999, 245, 205-227.	6.0	94
86	Biochemistry and physiology of the leukotrienes. Clinical Reviews in Allergy and Immunology, 1999, 17, 27-42.	6.5	13
87	The measurement of leukotrienes in human fluids. Clinical Reviews in Allergy and Immunology, 1999, 17, 153-177.	6.5	5
88	Antileukotrienes and laboratory models of asthma. Clinical Reviews in Allergy and Immunology, 1999, 17, 223-233.	6.5	0
89	Effect of DP-1904, a thromboxane synthetase inhibitor, on antigen- and spasmogen-induced bronchoconstriction in rodents. European Journal of Pharmacology, 1999, 366, 253-259.	3.5	3
90	Serum ECP and MPO, but not urinary LTE4, are associated with bronchial hyper-responsiveness. Respiratory Medicine, 1999, 93, 589-596.	2.9	1
91	LEUKOTRIENES, LEUKOTRIENE RECEPTOR ANTAGONISTS AND LEUKOTRIENE SYNTHESIS INHIBITORS IN ASTHMA: AN UPDATE. PART I: SYNTHESIS, RECEPTORS AND ROLE OF LEUKOTRIENES IN ASTHMA. Pharmacological Research, 1999, 40, 3-13.	7.1	52
92	LEUKOTRIENES, LEUKOTRIENE RECEPTOR ANTAGONISTS AND LEUKOTRIENE SYNTHESIS INHIBITORS IN ASTHMA: AN UPDATE. PART II: CLINICAL STUDIES WITH LEUKOTRIENE RECEPTOR ANTAGONISTS AND LEUKOTRIENE SYNTHESIS INHIBITORS IN ASTHMA. Pharmacological Research, 1999, 40, 15-29.	7.1	35

#	ARTICLE	IF	CITATIONS
93	Aspirin-induced asthma: Advances in pathogenesis and management. Journal of Allergy and Clinical Immunology, 1999, 104, 5-13.	2.9	313
94	Association of urinary leukotriene E4 excretion during aspirin challenges with severity of respiratory responses. Journal of Allergy and Clinical Immunology, 1999, 104, 559-564.	2.9	130
95	Dynamics of eicosanoids in peripheral blood cells during bronchial provocation in aspirin-intolerant asthmatics. European Respiratory Journal, 1999, 13, 638-646.	6.7	84
96	Leukotriene C4 Synthase: A Candidate Gene for the Aspirin-Intolerant Asthmatic Phenotype. Allergy and Asthma Proceedings, 1999, 20, 353-360.	2.2	10
97	Asma e leucotrienos. Revista Portuguesa De Pneumologia, 1999, 5, 487-497.	0.7	0
98	In Vivo Pharmacologic Profile of YM158, a New Dual Antagonist for Leukotriene D4 and Thromboxane A2 Receptors.. The Japanese Journal of Pharmacology, 2000, 83, 63-72.	1.2	8
99	Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. European Respiratory Journal, 2000, 16, 44-49.	6.7	171
100	The challenge procedure influences the extent of allergen-induced urinary excretion of leukotriene E4. Clinical and Experimental Allergy, 2000, 30, 585-589.	2.9	12
101	A moderate and unspecific release of cysteinyl leukotrienes by aspirin from peripheral blood leucocytes precludes its value for aspirin sensitivity testing in asthma. Clinical and Experimental Allergy, 2000, 30, 1785-1791.	2.9	45
102	Difference in urinary LTE4 and 11-dehydro-TXB2 excretion in asthmatic patients. Prostaglandins and Other Lipid Mediators, 2000, 62, 395-403.	1.9	17
103	In Vivo Pharmacologic Profile of YM158, a New Dual Antagonist for Leukotriene D4 and Thromboxane A2 Receptors. The Japanese Journal of Pharmacology, 2000, 83, 63-72.	1.2	0
104	Measurement of Leukotrienes in Humans. American Journal of Respiratory and Critical Care Medicine, 2000, 161, S102-S106.	5.6	66
105	Antileukotriene Therapy. American Journal of Respiratory and Critical Care Medicine, 2000, 161, S147-S153.	5.6	41
106	Treatment of Aspirin-intolerant Asthma with Antileukotrienes. American Journal of Respiratory and Critical Care Medicine, 2000, 161, S137-S141.	5.6	35
107	Sputum Cysteinyl Leukotrienes Increase 24 Hours after Allergen Inhalation in Atopic Asthmatics. American Journal of Respiratory and Critical Care Medicine, 2000, 161, 1553-1558.	5.6	86
108	Effects of 2 weeks of treatment with fluticasone propionate 100 mcg b.d. by comparison with zafirlukast 20 mg b.d. on bronchial hyper-responsiveness in patients with mild to moderate asthma. Respiratory Medicine, 2000, 94, 112-118.	2.9	27
109	Lack of effect of the 5-lipoxygenase inhibitor zileuton in blocking oral aspirin challenges in aspirin-sensitive asthmatics. Annals of Allergy, Asthma and Immunology, 2000, 85, 40-45.	1.0	52
110	Montelukast is only partially effective in inhibiting aspirin responses in aspirin-sensitive asthmatics. Annals of Allergy, Asthma and Immunology, 2000, 85, 477-482.	1.0	100

#	ARTICLE	IF	CITATIONS
111	5â€² Flanking region polymorphism of the gene encoding leukotriene C4 synthase does not correlate with the aspirin-intolerant asthma phenotype in the United States. Journal of Allergy and Clinical Immunology, 2000, 106, 72-76.	2.9	181
112	Natural history of aspirin-induced asthma. European Respiratory Journal, 2000, 16, 432.	6.7	494
113	Leukotrienes as Mediators of Asthma. Pulmonary Pharmacology and Therapeutics, 2001, 14, 3-19.	2.6	102
114	Effects of pranlukast on aspirin-induced bronchoconstriction: differences in chemical mediators between aspirin-intolerant and tolerant asthmatic patients. Annals of Allergy, Asthma and Immunology, 2001, 87, 74-79.	1.0	21
115	Leukotriene inhibitors and non-steroidal therapies in the treatment of asthma. Expert Opinion on Pharmacotherapy, 2001, 2, 47-65.	1.8	10
116	Intelligent use of NSAIDs - where do we stand?. Expert Opinion on Pharmacotherapy, 2001, 2, 19-30.	1.8	8
117	The Anti-inflammatory Effects of Leukotriene-Modifying Drugs and Their Use in Asthma. Chest, 2001, 119, 1533-1546.	0.8	108
118	Circadian Characteristics of Urinary Leukotriene E4 in Healthy Subjects and Nocturnal Asthmatic Patients. Chest, 2001, 120, 1822-1828.	0.8	17
119	Differential mediator release from basophils of allergic and nonâ€allergic asthmatic patients after stimulation with antiâ€IgE and C5a. Clinical and Experimental Allergy, 2001, 31, 368-378.	2.9	17
120	Release of cysteinyl leukotrienes with aspirin stimulation and the effect of prostaglandin E₂ on this release from peripheral blood leucocytes in aspirinâ€induced asthmatic patients. Clinical and Experimental Allergy, 2001, 31, 1615-1622.	2.9	71
121	Aspirin-Induced Asthma. Clinical Reviews in Allergy and Immunology, 2001, 21, 71-88.	6.5	9
122	Antiallergic effect of ardisiaquinone A, a potent 5-lipoxygenase inhibitor. Phytomedicine, 2001, 8, 460-464.	5.3	8
123	Leukotriene Modifiers in Pediatric Asthma Management. Pediatrics, 2001, 107, 381-390.	2.1	85
124	Pulmonary Gas Exchange and Sputum Cellular Responses to Inhaled Leukotriene D4in Asthma. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 202-206.	5.6	32
125	Increased Exhaled Cysteinyl-Leukotrienes and 8-Isoprostane in Aspirin-induced Asthma. American Journal of Respiratory and Critical Care Medicine, 2002, 166, 301-306.	5.6	186
126	Improvement of Aspirin-Intolerant Asthma by Montelukast, a Leukotriene Antagonist. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 9-14.	5.6	307
127	Leukotriene Receptor Antagonists. Seminars in Respiratory and Critical Care Medicine, 2002, 23, 399-410.	2.1	14
128	Leukotriene-Receptor Expression on Nasal Mucosal Inflammatory Cells in Aspirin-Sensitive Rhinosinusitis. New England Journal of Medicine, 2002, 347, 1493-1499.	27.0	351

#	ARTICLE	IF	CITATIONS
129	Analgesics and Asthma. American Journal of Therapeutics, 2002, 9, 233-243.	0.9	18
130	Leukotriene C4 synthase promoter polymorphism in Japanese patients with aspirin-induced asthma. Journal of Allergy and Clinical Immunology, 2002, 109, 936-942.	2.9	133
131	Exercise-Induced Bronchospasm in the Elite Athlete. Sports Medicine, 2002, 32, 583-600.	6.5	150
133	The mechanisms of aspirin-intolerant asthma and its management. Current Allergy and Asthma Reports, 2002, 2, 117-125.	5.3	8
134	Aspirin intolerance and nasal polyposis. Current Allergy and Asthma Reports, 2002, 2, 488-493.	5.3	44
135	Decreased apoptosis and distinct profile of infiltrating cells in the nasal polyps of patients with aspirin hypersensitivity. Allergy: European Journal of Allergy and Clinical Immunology, 2002, 57, 493-500.	5.7	59
136	Urinary metabolites of histamine and leukotrienes before and after placebo-controlled challenge with ASA and food additives in chronic urticaria patients. Allergy: European Journal of Allergy and Clinical Immunology, 2002, 57, 1180-1186.	5.7	33
137	Asthma, nasal polyposis and ulcerative colitis: a new perspective. Clinical and Experimental Allergy, 2002, 32, 1144-1149.	2.9	13
138	The effect of leukotriene-modifier drugs on aspirin-induced asthma and rhinitis reactions. Clinical and Experimental Allergy, 2002, 32, 1491-1496.	2.9	99
139	A comparative study of eicosanoid concentrations in sputum and urine in patients with aspirin-intolerant asthma. Clinical and Experimental Allergy, 2002, 32, 1484-1490.	2.9	59
140	Uncoupled regulation of leukotriene C4 synthase in platelets from aspirin-intolerant asthmatics and healthy volunteers after aspirin treatment. Clinical and Experimental Allergy, 2002, 32, 1566-1573.	2.9	17
141	Pathogenesis of Aspirin-Exacerbated Respiratory Disease. Clinical Reviews in Allergy and Immunology, 2003, 24, 169-188.	6.5	29
142	Nasal blockage and urinary leukotriene E4 concentration in patients with seasonal allergic rhinitis. Allergy: European Journal of Allergy and Clinical Immunology, 2003, 58, 476-480.	5.7	23
143	Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib. Journal of Allergy and Clinical Immunology, 2003, 111, 1116-1121.	2.9	133
144	Effects of cysteinyl leukotrienes and leukotriene receptor antagonists on markers of inflammation. Journal of Allergy and Clinical Immunology, 2003, 111, S49-S61.	2.9	30
146	High levels of urinary leukotriene E4 excretion in steroid treated patients with severe asthma. Respiratory Medicine, 2003, 97, 1225-1229.	2.9	39
147	Anti-leukotrienes: here to stay?. Current Opinion in Pharmacology, 2003, 3, 257-263.	3.5	19
148	Inhibitory effect of a leukotriene receptor antagonist (montelukast) on neurokinin a-induced bronchoconstriction. Journal of Allergy and Clinical Immunology, 2003, 111, 833-839.	2.9	24

#	ARTICLE	IF	CITATIONS
149	11-Dehydro-thromboxane B2, a Stable Thromboxane Metabolite, Is a Full Agonist of Chemoattractant Receptor-homologous Molecule Expressed on TH2 Cells (CRTH2) in Human Eosinophils and Basophils. Journal of Biological Chemistry, 2004, 279, 7663-7670.	3.4	93
150	Montelukast protects against nasal lysine-aspirin challenge in patients with aspirin-induced asthma. European Respiratory Journal, 2004, 24, 226-230.	6.7	35
151	Mechanisms of aspirin-sensitive asthma. Allergy International, 2004, 53, 111-119.	3.3	5
152	Urinary leukotriene E4 and 11-dehydro-thromboxane B2 excretion in children with bronchial asthma. Allergy International, 2004, 53, 127-134.	3.3	1
153	Additive effect of cysteinyl leukotriene or thromboxane modifiers to inhaled corticosteroids in asthmatic patients. Allergy International, 2004, 53, 211-217.	3.3	3
154	Urinary 3-bromotyrosine and 3-chlorotyrosine concentrations in asthmatic patients: lack of increase in 3-bromotyrosine concentration in urine and plasma proteins in aspirin-induced asthma after intravenous aspirin challenge. Clinical and Experimental Allergy, 2004, 34, 931-938.	2.9	58
155	Increase in urinary leukotriene B4 glucuronide concentration in patients with aspirin-intolerant asthma after intravenous aspirin challenge. Clinical and Experimental Allergy, 2004, 34, 1262-1269.	2.9	37
156	Urinary leukotriene E ₄ and 9 β - Δ^8 - Δ^9 -prostaglandin F ₂ concentrations in mild, moderate and severe asthma, and in healthy subjects. Clinical and Experimental Allergy, 2004, 34, 624-631.	2.9	30
157	Montelukast 10 mg improves nasal function and nasal response to aspirin in ASA-sensitive asthmatics: a controlled study vs placebo. Allergy: European Journal of Allergy and Clinical Immunology, 2004, 59, 289-294.	5.7	37
158	Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria) Involvement of chronic hyperplastic rhinosinusitis with nasal polyposis. Journal of Allergy and Clinical Immunology, 2004, 113, 277-283.	2.9	125
159	Montelukast protects against nasal lysine-aspirin challenge in patients with aspirin-induced asthma*1. Journal of Allergy and Clinical Immunology, 2004, 113, S35.	2.9	0
160	Aspirin-Induced Asthma. Clinical Pulmonary Medicine, 2004, 11, 1-5.	0.3	0
161	Non-steroidal anti-inflammatory drugs-induced urticaria and angioedema: more research on mechanisms needed. Clinical and Experimental Allergy, 2005, 35, 698-699.	2.9	5
162	Relation between bronchial responsiveness to inhaled leukotriene D4 and markers of leukotriene biosynthesis. Thorax, 2005, 60, 902-908.	5.6	24
163	Roflumilast as a treatment for COPD. Thorax, 2005, 60, 908-908.	5.6	0
164	Leukotriene D4-induced hypoxaemia in asthma is mediated by the cys-leukotriene1receptor. European Respiratory Journal, 2005, 26, 442-448.	6.7	21
165	Medications as asthma triggers. Immunology and Allergy Clinics of North America, 2005, 25, 169-190.	1.9	37
166	Determination of IgG subclasses: A need for standardization. Journal of Allergy and Clinical Immunology, 2005, 115, 872-874.	2.9	30

#	ARTICLE	IF	CITATIONS
167	Montelukast protects against bradykinin-induced bronchospasm. <i>Journal of Allergy and Clinical Immunology</i> , 2005, 115, 870-872.	2.9	11
168	Pathogenesis and Management of Aspirin-Intolerant Asthma. <i>Treatments in Respiratory Medicine</i> , 2005, 4, 325-336.	1.4	12
169	Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expression on nasal mucosal inflammatory cells. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 117, 312-318.	2.9	107
170	Clinical and pathologic perspectives on aspirin sensitivity and asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 118, 773-786.	2.9	291
171	Changes in urinary LTE4 and nasal functions following nasal provocation test with ASA in ASA-tolerant and -intolerant asthmatics. <i>Respiratory Medicine</i> , 2006, 100, 2144-2150.	2.9	19
172	Expression of 5-lipoxygenase and cyclooxygenase pathway enzymes in nasal polyps of patients with aspirin-intolerant asthma. <i>Journal of Pathology</i> , 2006, 209, 392-399.	4.5	85
173	Mechanisms of aspirin sensitivity. <i>Current Allergy and Asthma Reports</i> , 2006, 6, 198-202.	5.3	32
174	Prostanoids as pharmacological targets in COPD and asthma. <i>European Journal of Pharmacology</i> , 2006, 533, 89-100.	3.5	81
175	Hypersensitivity to Aspirin and Other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). <i>Current Pharmaceutical Design</i> , 2006, 12, 3347-3358.	1.9	36
176	Role of aspirin and other nonsteroidal anti-inflammatory drugs in aspirin-exacerbated respiratory disease. <i>Expert Review of Clinical Immunology</i> , 2006, 2, 75-86.	3.0	0
177	Urinary Leukotriene E4. <i>Immunology and Allergy Clinics of North America</i> , 2007, 27, 651-664.	1.9	48
178	The relationship between historical aspirin-induced asthma and severity of asthma induced during oral aspirin challenges. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 120, 273-277.	2.9	61
179	Alternative splicing of cyclooxygenase-1 gene: altered expression in leucocytes from patients with bronchial asthma and association with aspirin-induced 15-HETE release. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2007, 62, 628-634.	5.7	21
180	Quantification of leukotriene B4 glucuronide in human urine. <i>Prostaglandins and Other Lipid Mediators</i> , 2007, 83, 42-49.	1.9	8
181	Pharmacotherapy of diseases mediated by 5-lipoxygenase pathway eicosanoids. <i>Prostaglandins and Other Lipid Mediators</i> , 2007, 83, 188-197.	1.9	58
182	Possible involvement of mast cell activation in aspirin provocation of aspirin-induced asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2001, 56, 1061-1067.	5.7	81
183	Pathogenesis of Asthma. <i>Clinical and Experimental Allergy</i> , 2008, 38, 872-897.	2.9	614
184	Involvement of 15-lipoxygenase and prostaglandin EP receptors in aspirin-triggered 15-hydroxyeicosatetraenoic acid generation in aspirin-sensitive asthmatics. <i>Clinical and Experimental Allergy</i> , 2008, 38, 1108-1116.	2.9	17

#	ARTICLE	IF	CITATIONS
185	A novel antagonist of prostaglandin D ₂ blocks the locomotion of eosinophils and basophils. European Journal of Clinical Investigation, 2008, 38, 663-671.	3.4	30
186	TP receptor-mediated release of eosinophil chemotactic activity from human bronchial smooth muscle cells. European Journal of Pharmacology, 2008, 600, 133-139.	3.5	5
187	Systemic responses after bronchial aspirin challenge in sensitive patients with asthma. Journal of Allergy and Clinical Immunology, 2008, 121, 348-354.	2.9	31
188	Increase in inflammatory mediator concentrations in exhaled breath condensate after allergen inhalation. Journal of Allergy and Clinical Immunology, 2008, 122, 768-773.e1.	2.9	29
189	Effects of selective and non-selective COX inhibitors on antigen-induced release of prostanoid mediators and bronchoconstriction in the isolated perfused and ventilated guinea pig lung. Prostaglandins Leukotrienes and Essential Fatty Acids, 2008, 78, 89-97.	2.2	6
190	Leukotrienes and 8-isoprostane in exhaled breath condensate in bronchoprovocation tests with occupational allergens. Prostaglandins Leukotrienes and Essential Fatty Acids, 2008, 78, 281-292.	2.2	20
191	Prostaglandin E2 systemic production in patients with asthma with and without aspirin hypersensitivity. Thorax, 2008, 63, 27-34.	5.6	64
193	Leukotriene pathway polymorphisms are associated with altered cysteinyl leukotriene production in children with acute asthma. Prostaglandins Leukotrienes and Essential Fatty Acids, 2009, 81, 9-15.	2.2	15
194	Allergy Frontiers: Diagnosis and Health Economics. , 2009, , .		0
195	Leukotriene pathway in sickle cell disease: a potential target for directed therapy. Expert Review of Hematology, 2009, 2, 57-68.	2.2	18
196	Overexpression of the leukotriene C4 synthase gene in mice reproduces human aspirin-induced asthma. Nature Precedings, 2010, , .	0.1	0
197	Association analysis of thromboxane A synthase 1 gene polymorphisms with aspirin intolerance in asthmatic patients. Pharmacogenomics, 2011, 12, 351-363.	1.3	36
198	Lipoxygenase and Leukotriene Pathways: Biochemistry, Biology, and Roles in Disease. Chemical Reviews, 2011, 111, 5866-5898.	47.7	664
199	Increase in Salivary Cysteinyl-Leukotriene Concentration in Patients with Aspirin-Intolerant Asthma. Allergology International, 2011, 60, 37-43.	3.3	18
200	Management of nasal polyps in aspirin sensitive asthma triad. Current Opinion in Otolaryngology and Head and Neck Surgery, 2011, 19, 6-10.	1.8	8
201	Lipid Mediator Profiling in Pulmonary Disease. Current Pharmaceutical Biotechnology, 2011, 12, 1026-1052.	1.6	59
202	Effects of celecoxib on major prostaglandins in asthma. Clinical and Experimental Allergy, 2011, 41, 36-45.	2.9	38
203	Over-expression of the LTC4 synthase gene in mice reproduces human aspirin-induced asthma. Clinical and Experimental Allergy, 2011, 41, 1133-1142.	2.9	16

#	ARTICLE	IF	CITATIONS
204	Delayed Asthmatic Response to Bronchial Challenge with Allergen-Mediators, Eicosanoids, Eosinophil and Neutrophil Constituents in the Blood and Urine. <i>Respiration</i> , 2011, 82, 225-236.	2.6	13
205	Aspirin-Intolerant Asthma (AIA) Assessment Using the Urinary Biomarkers, Leukotriene E4 (LTE4) and Prostaglandin D2 (PGD2) Metabolites. <i>Allergology International</i> , 2012, 61, 393-403.	3.3	36
206	Exhaled Eicosanoids following Bronchial Aspirin Challenge in Asthma Patients with and without Aspirin Hypersensitivity: The Pilot Study. <i>Journal of Allergy</i> , 2012, 2012, 1-11.	0.7	16
207	Challenge of Isolated Sputum Cells Supports in vivo Origin of Intolerance Reaction to Aspirin/Non-Steroidal Anti-Inflammatory Drugs in Asthma. <i>International Archives of Allergy and Immunology</i> , 2012, 158, 299-306.	2.1	6
209	Urinary leukotriene E4 as a Biomarker of Exposure, Susceptibility and Risk in Asthma. <i>Immunology and Allergy Clinics of North America</i> , 2012, 32, 433-445.	1.9	19
210	Salbutamol but not ipratropium abolishes leukotriene D4-induced gas exchange abnormalities in asthma. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 1375-1383.	1.9	3
211	Quantitative metabolic profiling of lipid mediators. <i>Molecular Nutrition and Food Research</i> , 2013, 57, 1359-1377.	3.3	24
212	Quantification of Lipid Mediator Metabolites in Human Urine from Asthma Patients by Electrospray Ionization Mass Spectrometry: Controlling Matrix Effects. <i>Analytical Chemistry</i> , 2013, 85, 7866-7874.	6.5	44
213	Blocking of thromboxane A2 receptor attenuates airway mucus hyperproduction induced by cigarette smoke. <i>European Journal of Pharmacology</i> , 2013, 703, 11-17.	3.5	12
214	Application of "omics technologies to biomarker discovery in inflammatory lung diseases. <i>European Respiratory Journal</i> , 2013, 42, 802-825.	6.7	234
215	The Influence of Aspirin on Release of Eoxin C4, Leukotriene C4 and 15-HETE, in Eosinophilic Granulocytes Isolated from Patients with Asthma. <i>International Archives of Allergy and Immunology</i> , 2013, 162, 135-142.	2.1	27
216	Novel Therapies in Asthma. <i>American Journal of Therapeutics</i> , 2013, 20, 79-103.	0.9	29
217	Low prostaglandin E_2 and cyclooxygenase expression in nasal mucosa fibroblasts of aspirin-intolerant asthmatics. <i>Respirology</i> , 2013, 18, 711-717.	2.3	27
218	Upregulation of CD11b on Eosinophils in Aspirin Induced Asthma. <i>Allergology International</i> , 2013, 62, 367-373.	3.3	6
219	Leukotriene receptor antagonists pranlukast and montelukast for treating asthma. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 353-363.	1.8	32
221	Radar Signal Recognition Based on Manifold Learning Method. <i>International Journal of Control and Automation</i> , 2014, 7, 399-406.	0.3	3
222	Effects of selective COX-2 inhibition on allergen-induced bronchoconstriction and airway inflammation in asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 306-313.	2.9	45
223	Induced sputum eicosanoids during aspirin bronchial challenge of asthmatic patients with aspirin hypersensitivity. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, 1550-1559.	5.7	28

#	ARTICLE	IF	CITATIONS
224	Plasma apolipoprotein H levels are different between aspirin induced respiratory diseases and aspirin tolerant asthma. Pulmonary Pharmacology and Therapeutics, 2014, 27, 184-189.	2.6	4
226	Induced sputum supernatant bioactive lipid mediators can identify subtypes of asthma. Clinical and Experimental Allergy, 2015, 45, 1779-1789.	2.9	27
227	Mechanisms of aspirin hypersensitivity “What is known up to now. Alergologia Polska - Polish Journal of Allergology, 2015, 2, 15-20.	0.0	0
228	Practical Medical and Surgical Management of Chronic Rhinosinusitis. , 2015, , .		7
229	Aspirin Intolerance: Experimental Models for Bed-to-Bench. Current Drug Targets, 2016, 17, 1963-1970.	2.1	3
230	Biomarkers for the Phenotyping and Monitoring of Asthma in Children. Current Treatment Options in Allergy, 2016, 3, 439-452.	2.2	25
231	Leukotriene Receptor Antagonists and Antiallergy Drugs. Handbook of Experimental Pharmacology, 2016, 237, 153-169.	1.8	26
233	Utility of low-dose oral aspirin challenges for diagnosis of aspirin-exacerbated respiratory disease. Annals of Allergy, Asthma and Immunology, 2016, 116, 321-328.e1.	1.0	12
234	Platelet activation markers overexpressed specifically in patients with aspirin-exacerbated respiratory disease. Journal of Allergy and Clinical Immunology, 2016, 137, 400-411.	2.9	56
235	Potential Biomarkers for NSAID-Exacerbated Respiratory Disease. Mediators of Inflammation, 2017, 2017, 1-8.	3.0	14
236	Diagnostic Accuracy of Urinary LTE4 Measurement to Predict Aspirin-Exacerbated Respiratory Disease in Patients with Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 528-535.	3.8	40
237	The utility of biomarkers in diagnosis of aspirin exacerbated respiratory disease. Respiratory Research, 2018, 19, 210.	3.6	20
238	Urinary Leukotriene E4 as a Biomarker of Exposure, Susceptibility, and Risk in Asthma. Immunology and Allergy Clinics of North America, 2018, 38, 599-610.	1.9	19
239	Exposure to volatile organic compounds and airway inflammation. Environmental Health, 2018, 17, 65.	4.0	73
240	Prominent release of lipoxygenase generated mediators in a murine house dust mite-induced asthma model. Prostaglandins and Other Lipid Mediators, 2018, 137, 20-29.	1.9	7
241	Aspirin-exacerbated respiratory disease (AERD): Current understanding of AERD. Allergology International, 2019, 68, 289-295.	3.3	46
242	The Role of Leukotrienes as Potential Therapeutic Targets in Allergic Disorders. International Journal of Molecular Sciences, 2019, 20, 3580.	4.1	84
243	Eicosanoid mediator profiles in different phenotypes of nonsteroidal anti-inflammatory drug-induced urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1135-1144.	5.7	23

#	ARTICLE	IF	CITATIONS
244	Proinflammatory Pathways in the Pathogenesis of Asthma. Clinics in Chest Medicine, 2019, 40, 29-50.	2.1	83
245	IL-17“high asthma with features of a psoriasis immunophenotype. Journal of Allergy and Clinical Immunology, 2019, 144, 1198-1213.	2.9	80
246	Quantitative metabolic profiling of urinary eicosanoids for clinical phenotyping. Journal of Lipid Research, 2019, 60, 1164-1173.	4.2	20
247	Prostaglandin E ₂ decrease in induced sputum of hypersensitive asthmatics during oral challenge with aspirin. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 922-932.	5.7	18
248	Platelet-Adherent Leukocytes Associated With Cutaneous Cross-Reactive Hypersensitivity to Nonsteroidal Anti-Inflammatory Drugs. Frontiers in Pharmacology, 2020, 11, 594427.	3.5	3
249	Phase 2 trial of montelukast for prevention of pain in sickle cell disease. Blood Advances, 2020, 4, 1159-1165.	5.2	7
250	Urinary Leukotriene E ₄ and Prostaglandin D ₂ Metabolites Increase in Adult and Childhood Severe Asthma Characterized by Type 2 Inflammation. A Clinical Observational Study. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 37-53.	5.6	49
251	Urine Leukotriene E ₄ : Implications as a Biomarker in Chronic Rhinosinusitis. Otolaryngology - Head and Neck Surgery, 2022, 166, 224-232.	1.9	9
252	Leukotrienes in asthma. The potential therapeutic role of antileukotriene agents. Archives of Internal Medicine, 1996, 156, 2181-2189.	3.8	32
253	The Role of Eicosanoids in Inflammation and Allergy. , 0, , 233-272.		2
254	Some Recent Advances in Leukotriene Research. Advances in Experimental Medicine and Biology, 1997, 433, 1-7.	1.6	8
255	Genetic regulation of leukotriene production and activity. , 2002, , 137-166.		2
256	Platelets. , 2000, , 79-123.		1
257	Airway Smooth Muscle. Handbook of Experimental Pharmacology, 1994, , 405-444.	1.8	4
258	Diagnosis of Aspirin Sensitivity in Aspirin Exacerbated Respiratory Disease. , 2009, , 349-372.		3
259	Antileukotriene Therapy in Asthma. , 2009, , 1619-1632.		1
260	Hypersensitivity to Aspirin and Other Nonsteroidal Antiinflammatory Drugs. , 2014, , 1296-1309.		10
262	Asthma Therapy with Agents Preventing Leukotriene Synthesis or Action. Proceedings of the Association of American Physicians, 1999, 111, 547-559.	2.0	32

#	ARTICLE	IF	CITATIONS
263	A broad-spectrum lipidomics screen of antiinflammatory drug combinations in human blood. JCI Insight, 2016, 1, .	5.0	33
264	Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma.. Journal of Clinical Investigation, 1998, 101, 834-846.	8.2	485
265	Urinary LTE4 Levels as a Diagnostic Marker for IgE-Mediated Asthma in Preschool Children: A Birth Cohort Study. PLoS ONE, 2014, 9, e115216.	2.5	18
266	Unraveling the Genetic Basis of Aspirin Hypersensitivity in Asthma Beyond Arachidonate Pathways. Allergy, Asthma and Immunology Research, 2013, 5, 258.	2.9	50
267	Leukotriene Receptor Antagonists and 5-Lipoxygenase Inhibitors in Asthma. , 2000, , 171-189.		0
268	The Evolving Role of Leukotriene Modifiers as First Line Therapy in Mild Chronic Asthma: Modifying the Stepped Care Approach to Asthma. The Internet Journal of Asthma, Allergy and Immunology, 2002, 2, .	0.2	0
269	Leukotriene Modifiers in the Treatment of Asthma. , 2003, , 193-199.		0
270	Antileukotrienes in Asthma and Rhinitis. , 2009, , 63-90.		0
271	Antileukotriene Therapy in Asthma. , 2014, , 1602-1615.		0
272	New Therapies for Asthma. , 1997, , 259-277.		0
273	Leukotrienes in induced airway obstruction. , 1998, , 73-77.		0
274	Role of leukotrienes in aspirin-induced asthma. , 1998, , 79-88.		0
275	Interfering with the 5-Lipoxygenase Pathway as a Novel Way to Treat Asthma. , 1998, , 357-364.		0
276	How to measure leukotrienes in man. , 1998, , 43-54.		0
277	Leukotrienes in airways obstruction and inflammation evoked by allergen. , 1998, , 63-72.		0
278	Leukotrienes and aspirin-intolerant asthma. , 1999, , 165-175.		0
279	Leukotrienes and allergic asthma. , 1999, , 185-204.		0
280	Leukotriene Modulators. , 1999, , 285-328.		0

#	ARTICLE	IF	CITATIONS
281	Aspirin Desensitization and High-Dose Aspirin Therapy in Aspirin-Exacerbated Respiratory Disease. , 2015, , 313-322.		0
282	Oxygenated Lipid Products in COPD and Asthma: A Clinical Picture. , 2020, , 473-488.		0
284	Leukotriene and thromboxane antagonists. Clinical Reviews in Allergy, 1994, 12, 79-93.	1.0	6
285	LEVELS OF EICOSANOIDS IN NASAL SECRETIONS ASSOCIATED WITH NASAL POLYP SEVERITY IN CHRONIC RHINOSINUSITIS. Prostaglandins Leukotrienes and Essential Fatty Acids, 2022, , 102474.	2.2	4
286	ASPIRIN AND NONSTEROIDAL ANTI-INFLAMMATORY DRUGS. Immunology and Allergy Clinics of North America, 1995, 15, 529-552.	1.9	15
287	The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin in aspirin-sensitive asthmatics. European Respiratory Journal, 1993, 6, 1018-1026.	6.7	120
288	Effects of a 5-lipoxygenase inhibitor, ABT-761, on exercise-induced bronchoconstriction and urinary LTE4 in asthmatic patients. European Respiratory Journal, 1998, 11, 617-623.	6.7	37
289	Urinary Leukotriene E4 as a Biomarker in NSAID-Exacerbated Respiratory Disease (N-ERD): a Systematic Review and Meta-analysis. Current Allergy and Asthma Reports, 2022, 22, 209-229.	5.3	5
290	Unified Airway Disease. Otolaryngologic Clinics of North America, 2023, 56, 181-195.	1.1	4
291	DRUGS AFFECTING THE LEUKOTRIENE PATHWAY IN ASTHMA. International Journal of Clinical Practice, 1995, 49, 262-266.	1.7	3
292	Pharmacology of Leukotriene Receptor Antagonists and 5-lipoxygenase Inhibitors in the Management of Asthma. Pharmacotherapy, 1997, 17, .	2.6	2
293	Stratification of clinical and inflammatory phenotypes according to the urinary leukotriene E4 level in adult asthmatics. Allergy Asthma & Respiratory Disease, 2023, 11, 180.	0.2	0